Table 3.

Probabilities that observed mutations occur early^a or late^a for non-small-cell lung tumors (Ding et al., 2008)

Gene	Early (90% CI)	Late (90% CI)
APC	0.43 (0.08–1)	0.64 (0–0.97)
ATM	1 (0.57–1)	0 (0-0.51)
CDKN2A	0.08 (0.01–1)	0.97 (0.3–1)
EGFR	1 (0.84–1)	0 (0–0.19)
EPHA3	0.07 (0–0.17)	0.96 (0.87–1)
EPHA5	0.46 (0.07–1)	0.58 (0–0.95)
EPHA7	0.14 (0–1)	0.89 (0–1)
ERBB4	0.12 (0–0.32)	0.9 (0.68–1)
FGFR4	0.11 (0–1)	0.92 (0–1)
INHBA	1 (0–1)	0 (0–1)
KDR	0.04 (0–1)	0.97 (0–1)
KRAS	1 (1–1)	0 (0–0)
LRP1B	0.22 (0.04–1)	0.84 (0–0.97)
LTK	0.06 (0–1)	0.97 (0–1)
MYO3B	0.22 (0–1)	0.8 (0–1)
NF1	0.23 (0.06–1)	0.86 (0.54–0.98)
NRAS	1 (1–1)	0 (0–0.93)
NTRK1	1 (0.14–1)	0 (0–0.9)
NTRK2	0.11 (0–1)	0.93 (0–1)
NTRK3	1 (0–1)	0 (0–1)
PAK3	1 (0–1)	0 (0–1)
PTEN	1 (0.02–1)	0 (0–0.99)
PTPRD	0.44 (0.11–1)	0.6 (0–0.93)
RB1	0.08 (0–0.41)	0.96 (0.52–1)
STK11	1 (0.4–1)	0 (0–0.78)
TFDP1	1 (0.05–1)	0 (0–1)
TP53	0.97 (0.82–1)	0.07 (0–0.4)
ZMYND10	1 (1–1)	0 (0–1)

^aEarly means 1st, 2nd or 3rd event and late means later events.